Wechselwirkungen · Epoetin Alfa Hexal
Epoetin alfa HEXAL 1 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 2 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 3 000 IU/0.3 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 4 000 IU/0.4 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 5 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 6 000 IU/0.6 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 7 000 IU/0.7 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 8 000 IU/0.8 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 9 000 IU/0.9 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 10 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 20 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 30 000 IU/0.75 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 40 000 IU/1 mL solution for injection in a pre-filled syringe · Abschnitt 4.5 · PDF-Seite 15
HOS-117292 · Präparat HOS-094569
In female adult patients with metastatic breast cancer, subcutaneous co-administration of 40 000 IU/mL epoetin alfa with trastuzumab 6 mg/kg had no effect on the pharmacokinetics of trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trastuzumab (HOS-090897)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T12:53:00Z · SHA-256 601fb2973d7e0801e2f137c3ceb16c47233d34d04a9f0a0082b20983c4550a9e · Passage d84e75ada32f6a98168e61ace38ed8d038ba421d13afa6d955effd725aad0474 · Zeichen 752–946 im Abschnitt